Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05229237
Other study ID # START
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2018
Est. completion date December 5, 2021

Study information

Verified date April 2018
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4. Todescirbe the real situation and prognosis of PCV patients in our country.


Description:

1. To observe the visual changes in PCV patients receiving Conbercept treatment, so as to evaluate the effectiveness of the treatment. Changes of OCT, ICGA, quality of life and visual function would be observed and evaluated. 2. To observe and describe the characteristics of PCV. 3. To observe and describe the incidence of adverse events (AE) and serious adverse events (SAE) of Conbercept in the treatment of PCV, so as to evaluate the safety of this treatment. 4. To observe and descirbe the real situation and prognosis of PCV patients in our country.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date December 5, 2021
Est. primary completion date June 5, 2021
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - According to the current diagnostic criteria, diagnosed as PCV patients - Conbercept is used for treatment, and the recommended treatment scheme is 3+PRN - Local and systemic anti-VEGF therapy was not used for at least three months before enrollment - The patient volunteers to take part in this observational study, and signs the informed consent - The patient can follow-up regularly (at least 4 times of follow-up in one year) Exclusion Criteria: - The patient has serious systemic disease, and the current clinical treatment is contraindicated - Local or systemic anti-VEGF therapy was used for less than three months before enrollment - Existence of diseases unsuitable to accept intravitreal Conbercept, including uncontrolled hypertension and diabetes, AIDS, malignant tumors, active hepatitis, severe renal failure, severe mental, nerve, cardiovascular, respiratory and immune diseases - During six months before screening, there were cardiovascular events such as stroke, transient ischemic attack, myocardial infarction or acute congestive heart failure - Ocular contraindications, including active intraocular inflammation, infectious endophthalmitis, corneal ulcer, scleritis, uncontrolled glaucoma and so on - Patients who could not follow up regularly - Patients who refuse to sign the informed consent - Others

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Conbercept
Intravitral injection of Conbercept (0.5 mg/0.05 mL, Chengdu Kanghong Biotech, Inc.)

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual acuity Best corrected visual acuity using ETDRS chart (letter numbers) 6 months after the first Conbercept treatment
Secondary OCT and OCTA Changes of central retinal thickness and size of PED (µm) 12 months after the first Conbercept treatment
Secondary FFA&ICGA Changes of PCV lesions on ICGA (µm) 12 months after the first Conbercept treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01469156 - Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Recruiting NCT02597855 - Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography N/A
Completed NCT02495181 - Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Phase 4
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01248117 - Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT01884597 - Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Phase 1/Phase 2
Recruiting NCT04707027 - Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept N/A
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01871376 - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Phase 4
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Recruiting NCT00383812 - Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy N/A
Completed NCT00837330 - Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Not yet recruiting NCT04380974 - Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT02815176 - Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers N/A
Active, not recruiting NCT00344617 - Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Phase 3
Recruiting NCT03929731 - Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
Completed NCT01023295 - Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) Phase 2
Completed NCT02821520 - Initial Versus Delayed PDT Combination With Conbercept in PCV Phase 4